Radiofrequency Ablation for the Management of Liver Tumors

Gil N. Bachar MD,1 Franklin Greif MD,2 Eytan Mor MD,3 Ran Tur-Kaspa MD4,5 and Alexander Belenky MD PhD1

Departments of 1Radiology (Interventional Radiology Unit), 2Surgery A, 3Transplantation (Liver Transplantation Unit) and 4Medicine D, and 5Liver Institute, Rabin Medical Center (Beilinson Campus), Petah Tiqa, Israel
Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel

Key words: radiofrequency ablation, liver neoplasm, hepatocellular carcinoma, liver metastases

Abstract
Background: Radiofrequency ablation has recently become a viable treatment option for unresectable primary or secondary lesions confined to the liver.

Objective: To study the local therapeutic efficacy, side effects and complications of radiofrequency ablation for the treatment of hepatocellular carcinoma and liver metastases. This is the first reported experience of radiofrequency ablation for treating malignant hepatic tumors in Israel.

Methods: Fifteen consecutive patients, aged 53–73 years, with 23 lesions (8 patients with HCC and 7 with secondary liver tumors) underwent radiofrequency ablation under general anesthesia. RITA nine-array 5 cm thermal ablation catheter and the model 1500 generator were used. The mean diameter of all tumors was 4.28 cm (range 1–10 cm). Three lesions were 1–3 cm in diameter (small), 17 lesions measured 3.1–5 cm (medium), and 3 measured 5.1–10 cm (large).

Results: Complete necrosis was found in 8 (66%) of 12 HCCs by computed tomography scan. Of the remainder, diffuse tumor recurrence was demonstrated in three lesions (25%) after lipiodol injection and there was one local tumor recurrence. In the metastases group complete necrosis was found in 5 of 11 lesions (45%). One major complication (peritonitis) was treated with antibiotics and four (26%) minor complications (right pleural effusion, small subcapsular hematoma) were monitored.

Conclusions: Radiofrequency ablation appears to be an effective, safe and relatively simple procedure for the treatment of liver tumors.

Surgical resection is the gold standard for the treatment of primary or secondary tumors. However, only 10–20% of patients are candidates for curative resection [1] because of poor hepatic reserve resulting from coexisting liver cirrhosis or the presence of extensive tumor load. Since medical therapy is of limited benefit, regional treatment methods, such as microwave ablation [2], cryoablation [3], percutaneous ethanol injection [4], chemembolization, and radiofrequency ablation [5] have been suggested.

The aim of the present study was to assess the efficacy, safety and complications of RFA in treating malignant hepatic tumors. This is the first report of use of this method in Israel.

Indications and contraindications
RFA is a viable treatment option for focal and nodular or encapsulated tumors that are confined to the liver, without evidence of vascular invasion or extrahepatic metastases. Eligible patients must have a maximum of four to five lesions. For treatment in one session with one needle insertion, tumor size should ideally be up to 5 cm; larger lesions, especially hepatocellular carcinoma, can sometimes be treated in one session with multiple needle insertions.

In patients with lesions adjacent to the gallbladder or the hepatic hilum, in whom RFA poses a risk of thermal injury to the biliary tract, intraoperative RFA may be preferred. Furthermore, patients with lesions located near hepatic vessels, in whom the blood flow cools the vascular wall but the heat loss poses the risk of incomplete ablation of the area of necrotic tissue adjacent to the vessel, are also candidates for intraoperative RFA. Patients with multiple metastases in both lobes are better treated with partial hepatectomy and intraoperative RFA. Patients who are not considered eligible for RFA treatment are those with evidence of vascular invasion, extrahepatic metastases, or proximity of the mass to organs or large vessels. Patients with a high risk for general anesthesia or with pacemakers are also not considered eligible for treatment by RFA.

Patients and Methods
Patients and tumors
The study sample consisted of 15 consecutive patients (11 men and 4 women) aged 53–73 years (mean 62.1) who were referred to the Interventional Radiology Unit for RFA between November 2000 and December 2001. Eight patients had HCC and seven had secondary liver tumors (Table 1). Twelve underwent percutaneous RFA and 3 had intraoperative RFA. Nine patients (60%) had a single lesion, 4 (26%) had 2 lesions, 1 (6.6%) had 3 lesions, and 1 (6.6%) had 4 lesions – a total of 23 lesions. Hepatitis B surface antigen was positive in five patients (62.5%) and three (37.5%) were positive for hepatitis C virus. One patient also had alcoholic cirrhosis.

Tumors were classified according to the size and appearance of tumor margins. Diameter ranged from 1 to 10 cm (mean 4.28 cm). Three lesions measured 1–3 cm in diameter (small), 17 measured 3.1–5 cm (medium), and 3 measured 5.1–10 cm (large). Twenty tumors had smooth, well-circumscribed margins or were surrounded by a capsule at imaging and were classified as non-infiltrating. Three tumors had irregular margins or appeared non-encapsulated, and were classified as infiltrating. The goal of RFA was curative in patients with non-infiltrating tumors and palliative in patients with infiltrating tumors.
### Table 1. Characteristics of patients with hepatic tumor treated with radiofrequency ablation

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age/Gender</th>
<th>Disease</th>
<th>No. of lesions</th>
<th>Size (cm)</th>
<th>Time of procedure (min)</th>
<th>Hospital stay</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>73M</td>
<td>HCC</td>
<td>1</td>
<td>4.5</td>
<td>50</td>
<td>2</td>
<td>Subcapsular hematoma, pleural effusion</td>
</tr>
<tr>
<td>2</td>
<td>60M</td>
<td>HCC</td>
<td>2</td>
<td>4.5-5.5</td>
<td>90</td>
<td>1</td>
<td>None</td>
</tr>
<tr>
<td>3</td>
<td>53M</td>
<td>HCC</td>
<td>1</td>
<td>3.5</td>
<td>75</td>
<td>2</td>
<td>Mild pain</td>
</tr>
<tr>
<td>4</td>
<td>71M</td>
<td>HCC</td>
<td>2</td>
<td>3.5</td>
<td>90</td>
<td>5</td>
<td>Peritonitis</td>
</tr>
<tr>
<td>5</td>
<td>61F</td>
<td>HCC</td>
<td>1</td>
<td>4</td>
<td>45</td>
<td>2</td>
<td>None</td>
</tr>
<tr>
<td>6</td>
<td>64M</td>
<td>Diffuse HCC</td>
<td>3</td>
<td>4</td>
<td>120</td>
<td>4</td>
<td>Mild pain</td>
</tr>
<tr>
<td>7</td>
<td>62M</td>
<td>HCC</td>
<td>1</td>
<td>4.5</td>
<td>50</td>
<td>7</td>
<td>None</td>
</tr>
<tr>
<td>8</td>
<td>65M</td>
<td>HCC</td>
<td>1</td>
<td>4.5</td>
<td>70</td>
<td>2</td>
<td>None</td>
</tr>
<tr>
<td>9</td>
<td>71F</td>
<td>Colon metastases</td>
<td>2</td>
<td>4.2</td>
<td>90</td>
<td>3</td>
<td>None</td>
</tr>
<tr>
<td>10</td>
<td>57M</td>
<td>Thyroid metastases</td>
<td>4</td>
<td>4-5</td>
<td>120</td>
<td>2</td>
<td>Subpleural hematoma, pleural effusion</td>
</tr>
<tr>
<td>11</td>
<td>60M</td>
<td>Colon metastases</td>
<td>1</td>
<td>10</td>
<td>120</td>
<td>1</td>
<td>None</td>
</tr>
<tr>
<td>12</td>
<td>56M</td>
<td>Colon metastases</td>
<td>1</td>
<td>7</td>
<td>100</td>
<td>6</td>
<td>None</td>
</tr>
<tr>
<td>13</td>
<td>57F</td>
<td>Colon metastases</td>
<td>1</td>
<td>3</td>
<td>40</td>
<td>10</td>
<td>None</td>
</tr>
<tr>
<td>14</td>
<td>67F</td>
<td>Colon metastases</td>
<td>2</td>
<td>1.5, 3</td>
<td>60</td>
<td>5</td>
<td>None</td>
</tr>
<tr>
<td>15</td>
<td>60M</td>
<td>Colon metastases</td>
<td>1</td>
<td>4</td>
<td>50</td>
<td>2</td>
<td>None</td>
</tr>
</tbody>
</table>

### Work-up before the procedure

The work-up before the treatment included transabdominal gray-scale ultrasound with color Doppler using a 5000 HDI ultrasound scanner (Advanced Technology Laboratories, Bothell, WA, USA), equipped with a 2-4 MHz broadband convex-array transducer. Multiple sagittal and axial images of the liver were obtained. In addition, non-enhanced and dual-phase contrast-enhanced Multi Scan CT was performed using an Mx 8000 CT scanner (Marconi Medical Systems, Cleveland, OH, USA). A total of 120 ml non-ionic contrast medium (Ultravist 300 mg iodine/ml, Schering, Berlin, Germany) was injected into the median cubital vein with an automatic injector at a rate of 3-3.5 ml/sec. The entire liver was scanned twice: after 20 seconds (arterial phase) and after 70 seconds (portal phase) of contrast material injection.

The diagnosis of HCC was established by computed tomography scan after lipoidal injection, alpha-fetoprotein levels and fine-needle biopsy when needed. The diagnosis of metastasis was established by biopsy or a combination of ultrasound and CT, demonstrating the classic pictures in the presence of known primary disease in the colon, or the thyroid in one case.

Laboratory studies done 1 week before treatment consisted of complete blood count, renal panel, liver function panel, serum albumin, and tumor markers (alpha-fetoprotein and chorioembryonic antigen).

### Technique

All patients signed a written informed consent before the procedure. All procedures were performed in the radiologic interventional suite. The patients were under general anesthesia using ultrasound guidance (HDI 5000, Advanced Technology Laboratories) in the supine position. Vital signs were monitored during the procedure and for 1 hour thereafter. A diverse electrode was placed on the back and legs, the skin was cleansed with iodized alcohol, and the appropriate approach to the lesion was selected with the help of the ultrasound probe. An intercostal approach was usually preferred for lesions located in the right lobe and a subcostal approach for lesions in the left lobe. When the lesion was located at the apical edge of the liver in the subphrenic region or associated with planned resection, the procedure was done in the operating room (intraoperative RFA) through a laparotomy incision.

All ablations were performed with the RITA (Starburst XL) nine-array, 5 cm thermal ablation catheter (14 gauge needle 25 cm long) and the RITA model 1500 generator (RITA Medical Systems, Inc). The catheter tip was positioned at the intended ablation zone under sonographic guidance, and a nine-curved prong was deployed to deliver radiofrequency electrical energy to the tissues. The RITA generator was then operated. The total ablation time, impedance, and temperature at the tip of the prong were displayed on the device panel, and a complete output of the generator was redisplayed graphically on a laptop screen. The following ablation protocol was used: area of 3 cm in diameter – 105°C for 14.5 minutes, 4 cm area – 110°C for 14 minutes, and 5 cm area – 110°C for 7 minutes. The total ablation time for one needle insertion for a 5 cm lesion was 35 minutes; the overall ablation cycle was slightly longer because of the time needed to reach the target temperature. Tumors larger than 5 cm required two to four ablation cycles and, sometimes, multiple overlapping ablations. The ablation procedure was assessed in two ways. The first and more crucial was monitoring of the thermocouple temperatures during and after ablation. The second consisted of observing the outgasing of dissolved nitrogen into the heated tissue. As the tissue is heated, the solubility of the dissolved nitrogen decreases, resulting in microbubble formation within the tissue [Figure 1]. This appears as an echogenic blash that gradually enlarges to encompass the zone of ablation. The area of increased echogenicity progressively increased in size over the course of ablation and usually covered the entire tumor. The appearance and progression of the hyperechogenicity were used to guide the duration of therapy; radioenergy was applied until the tumor appeared completely hyperechogenic. Furthermore, in cases in which multiple electrode insertions were required, each subsequent electrode placement was directed to an area of the tumor where hyperechogenicity was not
evident. At the end of the procedure, as the needle was withdrawn, ablation was performed to coagulate the needle tract and prevent bleeding and tumor seeding.

**Follow-up**

Follow-up ranged from 1 to 12 months (mean 4 months). Visits were conducted 1 month after RFA and every 3 months thereafter, and included clinical evaluation and the same laboratory tests performed before the procedure. To evaluate the response to RFA, contrast-enhanced CT was performed with the same parameters as the pretreatment scanning. Every patient also underwent gray-scale and color Doppler ultrasound to evaluate tumor necrosis and identify residual viable tumor foci. Tumor necrosis was considered complete when no foci of enhancement were seen within the tumor or its periphery. Treatment was considered as a partial or complete failure when the residual tumor was detected on follow-up imaging or when the disease became diffuse, with enhancing tissue around the treated tumor in the same segment.

**Results**

Lesion size was 1–10 cm, and the number of needle insertions ranged from one to six. The procedures lasted 40–120 minutes. Patients were hospitalized for 1–5 days after the procedure, except for three patients who underwent laparotomy and required a stay of 3–10 days.

The eight patients in the primary HCC group had a total of 12 lesions. Contrast-enhanced CT performed 1 month after RFA showed complete necrosis in 8 (67%) of the 12 tumors. Of the remainder, three tumors (25%) showed diffuse spread on CT with lipiodol injection, and one showed local recurrence. The patients with diffuse disease were treated with chemotherapy or chemoembolization.

The metastases group consisted of seven patients with 11 lesions: six patients had colorectal liver metastases and one patient had medullary carcinoma of the thyroid with liver metastases. One patient in this group had a very large lesion (10 cm), which was treated with six needle insertions in one session.

The patient with thyroid carcinoma had eight metastases, which were treated in two sessions. Another patient underwent left lobectomy for liver metastases. Nine months later he had tumor recurrence in segment 8. Intraoperative RFA was performed because of the location of the tumor (Figure 2).

Two patients with ascites underwent catheter drainage before the procedure. In three selected patients, we performed intraoperative RFA because the lesion was located along the surface of the liver in a subphrenic area or near the great vessels or the hilum. One patient with multiple metastases in both lobes underwent partial hepatectomy of one lobe and intraoperative RFA in the other. Contrast-enhanced CT performed 1 month after treatment in the patients with metastases showed complete necrosis of 5 of the 11 metastases. In one patient with two metastases that were treated successfully, multiple additional metastases developed 1 month after treatment, and chemotherapy was given. Multiple metastases in the lungs were noted in the patient with thyroid carcinoma.

**Figure 2.** A 56 year old patient after left hepatic lobectomy for liver metastases. [A] Arterial phase CT scan obtained before RFA demonstrated a 7 cm hyperattenuating mass in segment 8 consistent with recurrence. [B] CT obtained 2 months after intraoperative RFA revealed complete ablation without recurrence.
Complications
Because the procedures were performed under general anesthesia, most of the patients had mild postprocedural pain, which was treated with oral analgesics. One patient had moderate pain requiring hospitalization for an extra day. In two patients (13.3%) a small asymptomatic right pleural effusion was noted which lasted less than 1 month, and two patients (13.3%) had a small subcapsular hematoma which was followed with ultrasound and resolved after 1–2 months. In the majority of patients, transaminase levels increased two to threefold over baseline levels during the first 3 days after the procedure and normalized by day 7. No significant changes in other laboratory parameters were observed.

During RFA, one patient with ascites was found to have hyperpyrexia with leukocytosis and peritonitis, which was treated with antibiotics. The duration of his hospital stay was 5 days.

Discussion
Of the procedures developed in recent years for the treatment of liver tumors, percutaneous ethanol injection has been shown to be safe and effective for nodular-type HCC (6,7), with a long-term outcome almost equal to that for resection. However, PEI cannot be applied to large HCC lesions or to lesions containing intranodal septa (because of alcohol diffusion within the tumor and because residual viable neoplastic tissue persists after the procedure). In addition, PEI was shown to be ineffective in the treatment of liver metastasis (8). A good alternative may be offered by percutaneous RFA (5,9), where energy at a frequency of 400–500 kHz is delivered into the tumor. The resulting electron vibrations within the tissue cause resistive heating. At temperatures over 50°C, the cell membranes melt and fuse, leading to protein denaturation and irreversible cell death (10). To the best of our knowledge, this is the first study describing the use of percutaneous RFA to treat primary and secondary liver tumors in Israel.

In the patients with primary HCC in the present series, the success rate (complete tumor necrosis) for RFA was 66%. This figure is close to the 71% success rate reported by Livraghi et al. (11) for tumors of similar size (3.1–5 cm in their study and 1–5.5 cm in ours), but considerably lower than the 90% reported by the same group for smaller tumors (1.0–3 cm) (12).

For large, secondary tumors, the present study shows that the technique used here has important advantages over other available percutaneous thermal (microwave, laser) therapies regarding the volume of tumor necrosis achieved and the procedure time (2,11–13). This is also true for PEI, which generally requires carefully planned multiple sessions to ensure that the ethanol is distributed throughout the tumor volume (12), and for conventional RFA, performed with a single monopolar electrode, which was capable of producing thermal necrosis in lesions not more than 1.6 cm in diameter and required several insertions to treat lesions of 5.0 cm or more. To overcome these limitations, we used a larger, nine-array, 5 cm ablation catheter with a newer-model generator. This enabled the creation of larger ablation sites without additional morbidity or mortality. We were thus able to treat 83% of the lesions with a single ablation cycle. The largest lesion in our series measured 10 cm, and the largest number of insertions required to treat a single lesion was six. The largest number of lesions treated in one patient in a single session was four. Nevertheless, to be considered for RFA treatment, the tumor must be confined to the liver, without evidence of vascular invasion or extrahepatic metastases. Tumor size should ideally be up to 5 cm, although larger lesions can be treated by multiple needle insertions. In addition, lesions located adjacent to the gallbladder or hepatic hilum or near large vessels risk causing thermal injury. Lesions located along the surface of the liver may be associated with a higher risk of complications and intraoperative RFA can be used. Patients with a high risk for general anesthesia or with pacemakers are also not considered eligible for treatment by RFA.

Livraghi et al. (14) and Casella et al. (15) reported that 4 of 32 patients (12.5%) who underwent RFA with a cooled-tip needle had biopsy-proven needle-tract seeding 4–18 months later. In light of this finding, in our study, using the RITA (Starburst XL) thermal ablation catheter and model 1500 generator, we performed tract ablation when the needle was withdrawn at the end of the procedure. After 12 months of follow-up we did not observe any neoplasm seeding along the tract.

To evaluate response to RFA, Livraghi et al. (12) performed contrast-enhanced CT 1 day and 1 month following treatment. They reported that during the portal phase of the 24 hour scan, a hyperattenuation surrounding the region of coagulated tumor was apparent in the majority of cases. They attributed this finding to reactive hyperemia rather than residual viable tumor. This assumption was supported by the disappearance of the rim on subsequent scans. In our protocol, we first evaluated response only 1 month following the procedure to avoid misinterpretation.

Livraghi and colleagues (11) performed all their RFA procedures under conscious sedation. One major complication occurred in a patient in whom severe hiccups led to erratic diaphragmatic movements during electrode placement, resulting in massive bleeding from the liver capsule and tumor. We used general anesthesia in all our patients and there were no major complications.

The absence of major complications is particularly noteworthy considering that our series consisted of several tumors near the hepatic capsule gallbladder and major blood vessels. We noted only a few minor complications: moderate pain leading to an increased hospital stay in one patient, and an asymptomatic right pleural effusion and small subcapsular hematoma in two patients each that resolved without treatment. One patient with ascites and peritonitis underwent drainage of 10 L of fluid before RFA and was treated with antibiotics. In three patients with lesions located along the surface of the liver in a subphrenic area or near great vessels or the hilum, we performed intraoperative RFA. All outcomes were successful, although hospitalization was longer than for percutaneous RFA (2–10 days versus 1–5 days).

In summary, RFA, a relatively new, minimally invasive modality for the thermal treatment of hepatic tumors, appears to be effective, safe and easy to use. It is associated with only a few complications. Our current department policy considers RFA the
treatment of choice for inoperable nodular-type HCC and metachronous metastases. Nevertheless, further investigation is warranted before definitive recommendations can be made.

References


Correspondence: Dr. G.N. Bachar, Det. of Radiology, Rabin Medical Center (Beilinson Campus), Petah Tiqwa 49100, Israel.
Phone: (972-3) 937-7090
Fax: (972-3) 937-7095
email: dbachar@netvision.net.il

---

**Capsule**

**Designing an anti-SARS drug**

Anand et al. present two crystal structures: the protease from human coronavirus 229E (one of the causative agents of the common cold) and the protease from a pig coronavirus in complex with a peptide inhibitor. They used these data to build a model of the homologous protease from the recently identified and sequenced SARS coronavirus, and confirm that the expressed recombinant SARS coronavirus protease displays the predicted enzyme activity. From the modeled structure, they suggest that the existing small molecule AG7008, currently in clinical trials as a treatment for rhinovirus (another causative agent of the common cold), may be a good starting point for developing SARS therapeutics.

*Science* 2003;300:1763
E. Israeli

---

**Capsule**

**Vaccination and autoimmune disease: what is the evidence?**

As many as one in 20 people in Europe and North America have some form of autoimmune disease. These diseases arise in genetically predisposed individuals but require an environmental trigger. Of the many potential environmental factors, infections are the most likely cause. Microbial antigens can induce cross-reactive immune responses against self-antigens, whereas infections can non-specifically enhance their presentation to the immune system. The immune system uses fail-safe mechanisms to suppress infection-associated tissue damage and thus limits autoimmune responses. The association between infection and autoimmune disease has, however, stimulated a debate as to whether such diseases might also be triggered by vaccines. Indeed there are numerous claims and counter-claims relating to such a risk. Wraith et al. review the mechanisms involved in the induction of autoimmunity and assess the implications for vaccination in humans.

*Lancet* 2003;361:Online June 3
E. Israeli